Free shipping on all orders over $ 500

NHWD-870 

Cat. No. M29257

All AbMole products are for research use only, cannot be used for human consumption.

NHWD-870  Structure

Price and Availability

For this product's availability, delivery time and price, please email inquiry@abmole.com directly or click the "Inquiry Now" button below.


Quality Control & Documentation
Biological Activity

NHWD-870 is a potent, orally active and selective BET family bromodomain inhibitor and only binds bromodomains of BRD2, BRD3, BRD4 (IC50=2.7 nM), and BRDT. NHWD-870 has potent tumor suppressive efficacies and suppresses cancer cell-macrophage interaction. NHWD-870 increases tumor apoptosis and inhibits tumor proliferation.

Chemical Information
Molecular Weight 491.59
Formula C29H29N7O
CAS Number 2115742-03-3
Form Solid
Solubility (25°C) DMSO 62.5 mg/mL (ultrasonic and warming and heat to 60°C)
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Mingsong Shi, et al. Phys Chem Chem Phys. The binding mechanism of NHWD-870 to bromodomain-containing protein 4 based on molecular dynamics simulations and free energy calculation

[2] Yafei Jiang, et al. Front Oncol. Bromodomain Inhibition Attenuates the Progression and Sensitizes the Chemosensitivity of Osteosarcoma by Repressing GP130/STAT3 Signaling

[3] Mingzhu Yin, et al. Nat Commun. Potent BRD4 inhibitor suppresses cancer cell-macrophage interaction

[4] Benjamin Bian, et al. Front Oncol. Pancreatic Cancer Organoids for Determining Sensitivity to Bromodomain and Extra-Terminal Inhibitors (BETi)

Related Epigenetic Reader Domain Products
RVX-208

Apabetalone (RVX-208) is a first-in-class, small molecule inhibitor of BET bromodomain with IC50 of 0.51 μM for BD2.

I-BET151

I-BET151 (GSK1210151A) is an inhibitor of the BET family with IC50 of 0.5 μM, 0.25 μM and 0.79 μM for BRD2, BRD3 and BRD4, respectively.

(+)-JQ1

(+)-JQ1 is a BET bromodomain inhibitor that acts on BRD4(2) with an IC50 of 33 nM and binds to all bromodomain domains in the BET family, but not to bromodomain domains outside the BET family. JQ1 down-regulates CD47 expression through a C-MYC-mediated pathway, and JQ1 down-regulates CD47 expression through a C-MYC-mediated pathway.

I-BET-762

I-BET-762 (GSK525762) is a selective small molecule BET inhibitor.

CPI-0610

CPI-0610 is a novel BET protein bromodomain inhibitor.

  Catalog
Abmole Inhibitor Catalog




Keywords: NHWD-870  supplier, Epigenetic Reader Domain, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.